Skip to main content
CON
NYSE Industrial Applications And Services

Concentra Lifts FY26 Guidance and Authorizes New $250M Buyback After 8.6% Q3 Revenue Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$42
Mkt Cap
$5.375B
52W Low
$18.545
52W High
$44.22
52W Position info
126% above low
Off High info
5.0% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

CON has more than doubled off its 52-week low of $18.545.

Summary

Concentra grew Q3 revenue 8.6% to $622.1 million and EPS 36.8% to $0.52, raised FY26 revenue and Adjusted EBITDA guidance, and authorized a new $250 million share repurchase program alongside a $0.0625 quarterly dividend.


Key Events · Earnings and Guidance · CON

  • Q3 Revenue Up 8.6% to $622.1M

    Revenue climbed to $622.1 million from $572.8 million, while net income attributable to the Company rose 36.5% to $65.9 million and EPS advanced 36.8% to $0.52.

  • FY26 Guidance Raised

    The revenue outlook was lifted to $2.360-$2.380 billion from $2.325-$2.375 billion, and Adjusted EBITDA to $505-$510 million from $485-$495 million; free cash flow guidance of $220-$240 million was reiterated.

  • New $250M Buyback Authorized

    The Board authorized a new $250 million repurchase program with no expiration date, in addition to the existing November 2025 program; 1.0 million shares were bought for $34.65 million in Q3.

  • Leverage Down to 2.90x

    A $52.4 million repayment on the term loan due 2031 cut net leverage to 2.90x; S&P upgraded the credit rating to BB and Moody's revised its outlook to positive.


Analysis · CON · Industrial Applications And Services

Top-line strength was only part of the story: Concentra pushed full-year revenue guidance to $2.360-$2.380 billion from $2.325-$2.375 billion, with Adjusted EBITDA now $505-$510 million versus $485-$495 million previously. For the share count, the bigger news is a fresh $250 million repurchase authorization layered on top of the existing November 2025 program, backed by $32.2 million of quarterly free cash flow and leverage down to 2.90x. Rising profit, deleveraging and a larger buyback — that combination is what supports the stock, not the headline revenue number alone.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CON was trading at $42.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $18.55 to $44.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CON - Latest Insights

CON
Nov 05, 2026, 5:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.99
Real-time Price: $41.40 info
Change: -$0.590 (-1%) info
Market Cap: $5.244B info
CON
Nov 05, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $41.91
Real-time Price: $41.40 info
Change: -$0.5055 (-1%) info
Market Cap: $5.244B info
CON
Aug 24, 2026, 4:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $34.99
Real-time Price: $41.40 info
Change: +$6.41 (+18%) info
Market Cap: $5.244B info
CON
Aug 06, 2026, 5:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.54
Real-time Price: $41.40 info
Change: +$10.86 (+36%) info
Market Cap: $5.244B info
CON
Aug 06, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.54
Real-time Price: $41.40 info
Change: +$10.86 (+36%) info
Market Cap: $5.244B info